Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14142238 | 0.89 | TDO2 (0.32) | TDO2AKR1C3AKR1C2CNR1CNR2 | |
| SCHEMBL19313295 | 0.83 | CNR2 (0.36) | CNR1CNR2ALDH1A1 | |
| SCHEMBL14645947 | 0.77 | RXRB (0.34) | — | |
| SCHEMBL14141860 | 0.76 | — | — | |
| SCHEMBL15810239 | 0.75 | TDO2 (0.33) | TDO2AKR1C3AKR1C2CNR1CNR2 | |
| SCHEMBL690593 | 0.72 | TSHR (0.36) | AKR1C3AKR1C2ALDH1A1SMN1; SMN2 | |
| SCHEMBL14142022 | 0.71 | PTAFR (0.36) | — | |
| SCHEMBL6031753 | 0.70 | RXRB (0.36) | ALDH1A1 | |
| SCHEMBL29594786 | 0.70 | RXRB (0.36) | ALDH1A1 | |
| SCHEMBL18649466 | 0.69 | ACHE (0.33) | TDO2AKR1C3AKR1C2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988323-B2 | Catalyst | BOREALIS AG (AT) | 2018-06-05 | — | — | US | disclosed |
| US-9988323-B2 | Catalyst | BOREALIS AG (AT) | 2018-06-05 | — | — | US | disclosed |
| EP-2746301-B1 | Catalyst | BOREALIS AG (AT) | 2018-05-30 | — | — | EP | disclosed |
| EP-2935295-B1 | CATALYST | BOREALIS AG (AT) | 2018-02-07 | — | — | EP | disclosed |
| EP-2729479-B1 | CATALYSTS | BOREALIS AG (AT) | 2017-09-06 | — | — | EP | disclosed |
| EP-2729479-B1 | CATALYSTS | BOREALIS AG (AT) | 2017-09-06 | — | — | EP | disclosed |
| US-20170137343-A1 | Catalyst | BOREALIS AG (AT) | 2017-05-18 | — | — | US | disclosed |
| US-20170137343-A1 | Catalyst | BOREALIS AG (AT) | 2017-05-18 | — | — | US | disclosed |
| US-9630980-B2 | Asymmetrical ligands | BOREALIS AG (AT) | 2017-04-25 | — | — | US | disclosed |
| US-9630980-B2 | Asymmetrical ligands | BOREALIS AG (AT) | 2017-04-25 | — | — | US | disclosed |
| US-9187583-B2 | Catalysts | BOREALIS AG (AT) | 2015-11-17 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| US-20140221584-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-08-07 | — | — | US | disclosed |
| WO-2014096166-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096166-A1 | CATALYSTS | BOREALIS AG (AT) | 2014-06-26 | — | — | WO | disclosed |
| EP-2746301-A1 | Catalyst | Borealis AG (AT) | 2014-06-25 | — | — | EP | disclosed |
| EP-2746301-A1 | Catalyst | Borealis AG (AT) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013007650-A1 | CATALYSTS | BOREALIS AG (AT) | 2013-01-17 | — | — | WO | disclosed |
| EP-2532687-A2 | Bridged Metallocene Catalysts | Borealis AG (AT) | 2012-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137343-A1 | Catalyst | C5, POR, C9 | TDO2 1146/4885AKR1C3 71/4885AKR1C2 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.